Scott Halperin, PharmD

home / authors / scott-halperin-pharmd

Articles

How the Complexities, Trends in Drug Benefit Design Are Evolving in Real Time

Brian Nowosielski;Morgan Lee, PhD, MPH, CPH;Scott Halperin, PharmD

June 26th 2025

With the emergence of increased GLP-1 use and alternative PBM models, Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, joined Drug Topics to discuss current trends in drug benefit design.

GLP-1s Serving as the Intersection of Cost, Utilization

Brian Nowosielski;Morgan Lee, PhD, MPH, CPH;Scott Halperin, PharmD

June 25th 2025

Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.

Q&A: PBM Unbundling, New Pricing Models Create More Transparency

Brian Nowosielski;Morgan Lee, PhD, MPH, CPH;Scott Halperin, PharmD

June 24th 2025

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.

How Drug Benefit Design Trends Are Expected to Impact Pharmacists

Brian Nowosielski;Morgan Lee, PhD, MPH, CPH;Scott Halperin, PharmD

June 23rd 2025

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss the 2025 Trends in Drug Benefit Design Report and how it will impact pharmacists.